We have recently been advised that Novartis Pharmaceuticals will suspend its financial support of plasma level testing after receiving a letter from the FDA criticizing its promotion of such testing on its CML & GIST Alliance websites. In response, Novartis has closed both websites and advised Avantix Laboratory it was ending its contract for such testing effective September 30, 2010.
What next?
The Life Raft Group has since met with Dr. Lynyee Shum, Director of Avantix Laboratory (TDM Pharmaceutical Research) and Herve Hoppenot, President of Novartis Oncology to discuss our concerns about this decision. We will keep our readers advised
